A Phase IV Open-labelled, Single-centered, Stratified-randomized Clinical Trial in Zhejiang Province to Evaluate the Safety and Immunogenicity of EV71 Vaccine Developed by Sinovac Biotech Co., Ltd.
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- The seroconversion rate of EV71 neutralizing antibody 30 days after the two doses vaccination
研究概览
简要总结
The purpose of this study is to evaluate the immunogenicity and safety of EV71 vaccine in infants aged 6 to 35 months old, by detecting the dynamic changes of neutralizing antibody at different time after vaccination
详细描述
This study is an open-labelled, single-centered, stratified-randomized, phase IV clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of EV71 vaccine (developed by Sinovac Biotech Co., Ltd.) in infants aged 6 to 35 months old, by detecting the dynamic changes of neutralizing antibody at different times after vaccination. The enrolled subjects in this study receive two doses of EV71 vaccine with 1-month interval between doses. To evaluate safety of the vaccine, subjects will be observed for 30 days after the injection for the potential adverse events. To evaluate the immunogenicity of the vaccine, venous blood will be collected for the neutralizing antibody detection prior to vaccination, 10/20/30 days after the 1st dose and 30 days after the 2nd dose vaccination. All subjects will receive blood sampling for three times. Subjects will be randomly assigned to receive blood sampling at 10/20/30 days after 1st dose injection, with a ratio of 1: 1: 1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 6 Months 至 35 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy volunteers aged 6-35 months old
- •Guardian(s) of the volunteer should be capable of understanding the written consent form, and such form should be signed before the infant being included into this study
- •Proven legal identity
排除标准
- •For subjects with any of the following conditions, vaccination should not be administrated:
- •History of hand foot and mouth disease
- •Allergy to gentamicin; history of allergy to any vaccine or vaccine ingredient, or serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, pain, etc
- •Severe chronic diseases
- •Thrombocytopenia or hemorrhagic disease
- •Immunodeficiency disease or receipt of immunosuppressant treatment
- •Uncontrolled epilepsy or progressive neurological disorders(e.g. Guillain-Barre syndrome)
- •Acute disease or acute stage of chronic disease prior to the study entry
- •History of thyroidectomy, thyroid disease within 12 months prior to the study entry
- •Asplenia or functional asplenia
- •Axillary temperature >37.0 ℃
- •Any other factor that suggesting the volunteer is unsuitable for this study based on the judgment of investigators
- •Exclusion Criteria of the Second Injection:
- •Subjects with any of the following conditions are forbidden to continue the 2nd dose of vaccination:
- •Any serious adverse event that has a causal relationship with the investigated vaccine
- •Severe allergic reactions or hypersensitivity after vaccination (including urticaria / rash appear within 30 minutes after vaccination
- •Any confirmed or suspected autoimmune disease or immunodeficiency disease (e.g., HIV infection)
- •Other reactions (including severe pain, severe swelling, severe activity limitation, persistent hyperthermia, severe headache or other systemic or local reactions)determined by the investigators
- •For subjects suffering from acute disease or acute stage of chronic disease , whether to continue vaccination depends on themselves
- •Subjects with the following conditions may receive vaccination in delayed time or withdraw from the study depending on the judgment of investigator
- •Acute disease (moderate or severe disease with or without fever) in case of vaccination
- •Axillary temperature > 37.0 °C
研究组 & 干预措施
EV71 vaccine & blood sampling (0, 10,60)
This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 10, and 60 respectively for EV71 neutralizing antibody detection.
干预措施: EV71 vaccine (Biological)
EV71 vaccine & blood sampling (0, 20,60)
This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 20, and 60 respectively for EV71 neutralizing antibody detection.
干预措施: EV71 vaccine (Biological)
EV71 vaccine& blood sampling (0, 30, 60)
This group receive two doses injection of EV71 vaccine (0, 28 days), and three times of blood sampling on day of 0, 30, and 60 respectively for EV71 neutralizing antibody detection.
干预措施: EV71 vaccine (Biological)
结局指标
主要结局
The seroconversion rate of EV71 neutralizing antibody 30 days after the two doses vaccination
时间窗: 30 days
Immunogenicity indicator
次要结局
- The seropositive rate of EV71 neutralizing antibody 10, 20, 30, and 60 days after the first dose vaccination(10, 20,30,and 60 days)
- Incidence of the serious adverse events within 60 days after the first dose vaccination(60 days)
- The seroconversion rate of EV71 neutralizing antibody 10, 20 and 30 days after the first dose vaccination(10,20,and 30 days)
- GMT and GMT increase fold of EV71 neutralizing antibody 10,20,30,and 60 days after the first dose vaccination(10,20，30，and 60 days)
- Incidence of unsolicited local or systemic adverse events within 3 days after each dose(3 days)
- Incidence of unsolicited adverse events within 30 days after each dose(30 days)